October 4, 2022
Loading...
You are here:  Home  >  Latest news  >  Current Article

Amgen adds two cancer treatment biosimilars to the market

IN THIS ARTICLE

Two oncology biosimilars from Thousand Oaks-based biotech giant Amgen hit the U.S. market July 18, copying Roche treatments for several types of cancer. Mvasi, Amgen’s second biosimilar to reach the market and the first oncology biosimilar to be approved by the U.S. Food and Drug Administration, was released to treat five types of cancer, including…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.